Welcome to our dedicated page for Materialise news (Ticker: MTLS), a resource for investors and traders seeking the latest updates and insights on Materialise stock.
Materialise NV reports developments in additive manufacturing software, 3D printing services, and 3D-printed medical devices. The Belgium-based foreign issuer trades on Nasdaq through ADSs and has ordinary shares listed on Euronext Brussels. Company updates commonly cover operating and financial results, segment trends in Materialise Medical, Materialise Software, and Materialise Manufacturing, and the role of 3D printing solutions across healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods.
Recurring announcements also include earnings-call schedules, annual and extraordinary shareholder meeting actions, regulated information under Belgian market rules, voting-rights and share-count notices, and changes affecting specific activities within the company’s 3D printing portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Materialise NV (NASDAQ:MTLS) reported robust financial results for Q1 2023, with total revenue increasing 24.4% to 65,886 kEUR, compared to 52,961 kEUR in Q1 2022. Adjusted EBITDA significantly rose 89% to 10,310 kEUR, reflecting strong performance across its segments. The company achieved a net profit of 3,715 kEUR, a substantial increase from 127 kEUR in the previous year. Revenue from Materialise Medical surged 32.5% to 24,317 kEUR, while Materialise Manufacturing saw a growth of 25.2%. Despite rising operational expenses by 8.7%, gross profit grew to 36,837 kEUR, reflecting a gross margin of 55.9%. Looking ahead, the company raised its 2023 revenue guidance, projecting results closer to the high end of its previous estimate.